PharmaJet, Inc.

World Vaccine Congress – Europe 2024 presentation, Improving Performance of Vaccines with Needle-free Technology will highlight the results of recent studies using needle-free delivery across infectious disease, oncology, and autoimmune disease indications. Published data from multiple partners will be shared demonstrating improved immune responses, safety pro and clinical performance with vaccines administered with needle-free precision-delivery technologies. Presentation scheduled for October 29 at 1:40 pm GMT in Theatre 1 at Fira de Barcelona Montjuïc in Barcelona, Spain. GOLDEN, Colo.--(BUSINESS WIRE)-- PharmaJet ® , a company that strives to improve the performance and outcomes of injectables with its enabling technology, today announced that they will share their latest research results at the World Vaccine Congress – Europe on October 29, 2024 at 1:40 pm GMT. The presentation, entitled Improving Performance of Vaccines with Needle-free Technology will be presented by Nathalie Landry, Chief Scientific Officer, PharmaJet. The PharmaJet Needle-free Systems are increasingly being incorporated into clinical studies across multiple infectious disease and oncology development programs, with over 52 studies and 49 partners. “The body of evidence continues to grow on how PharmaJet’s needle-free delivery can improve the performance of prophylactic and therapeutic vaccine candidates,” said Nathalie Landry, Chief Scientific Officer, PharmaJet. “When it comes to administering vaccines and therapeutics, the important outcomes are increased immunogenicity and enhanced protection from disease. The data shows that needle-free can be expected to enhance immune responses.” For more information about PharmaJet visit Booth #71 at the conference or visit the website . Refer to Instructions for Use to ensure safe injections and to review risks. About PharmaJet The PharmaJet mission is to improve the performance and outcomes of injectables with our enabling technology that better activates the immune system. We are committed to helping our partners realize their research and commercialization goals while making an impact on public health. PharmaJet Precision Delivery Systems™ can improve vaccine effectiveness, allow for a preferred patient and caregiver experience, and offer a proven path to commercialization. They are also safe, fast, and easy-to-use. The Stratis ® System has U.S. FDA 510(k) marketing clearance, CE Mark, and WHO PQS certification to deliver medications and vaccines either intramuscularly or subcutaneously. The Tropis ® System has CE Mark and WHO PQS certification for intradermal injections. They are both commercially available for global immunization programs. For more information or if you are interested in partnering with PharmaJet to improve the impact of your novel development program, visit or contact PharmaJet here . Follow us on LinkedIn . Contacts Nancy Lillie Nancy.Lillie@pharmajet.com 1-888-900-4321 Option 3

GOLDEN, Colo.--( BUSINESS WIRE )-- PharmaJet ® , a company that strives to improve the performance and outcomes of injectables with its enabling technology, today announced that it has entered into a long-term license and supply agreement with Scancell Holdings plc (LSE – SCLP.L) to use the US FDA 510(k)-cleared / CE-marked PharmaJet Stratis ® Intramuscular (IM) Needle-free System for the delivery of its advanced melanoma DNA vaccine (Immunobody ® SCIB1/iSCIB1+). Under the terms of the agreement, Scancell will use Stratis for the clinical development and commercialization of their advanced melanoma DNA vaccine. PharmaJet will receive development and regulatory milestone payments, and upon commercialization, will also receive royalties on net sales. Scancell will be responsible for the clinical and regulatory development as well as commercialization of the combined product. PharmaJet has commercially scaled their needle-free delivery technology that enhances the performance of nucleic acid vaccines and therapeutics. Stratis delivery has shown to enable an effective uptake of the Scancell DNA melanoma vaccine by native cellular machinery to express the target antigen and induce a potent anti-tumor response. To date, 60 patients across 15 clinical sites have successfully received a total of 171 doses of SCIB1/iSCIB1+ via Stratis. The combination of SCIB1/iSCIB1+ vaccine with Stratis offers patients the convenience of an off-the-shelf therapeutic cancer vaccine with the speed and enhanced patient experience of needle-free delivery. “Securing long term supply for the PharmaJet Stratis Needle-free Injection System is important to allow clinical and commercial development of iSCIB1+. We are pleased that PharmaJet delivery works effectively with the SCIB1/iSCIB1+ therapeutic cancer vaccines and offers a well-received immunization for patients,” commented Professor Lindy Durrant, Chief Executive Officer, Scancell. “Our ultimate goal for Scancell has been to deliver an off-the-shelf, safe, tolerable, effective therapy that can provide potent and durable anti-tumour responses for unresectable stage IV melanoma which currently has a 5-year survival of 35%, according to the SEER database .” A review article 1 recently published in Vaccines Journal (MDPI) identified that PharmaJet needle-free delivery provides improved tissue distribution and cellular uptake of vaccines. DNA vaccines delivered needle-free also tend to elicit improved immunogenicity compared with needles. “The Scancell strategic partnership further solidifies PharmaJet’s commercial delivery platform as a leader in the delivery of nucleic acid vaccines and immunotherapies,” said Nathalie Landry, Chief Scientific Officer at PharmaJet. “We look forward to working with Scancell to advance their innovation further in clinical development and commercialization for the ultimate benefit of melanoma patients worldwide.” For more information about PharmaJet visit https://pharmajet.com . Refer to Instructions for Use to ensure safe injections and to review risks. 1 Ledesma-Feliciano, C et al, Improved DNA Vaccine Delivery with Needle-free Injection Systems , Vaccines 2023, 11(2), 280 About PharmaJet The PharmaJet mission is to improve the performance and outcomes of injectables with our enabling technology that better activates the immune system. We are committed to helping our partners realize their research and commercialization goals while making an impact on public health. PharmaJet Precision Delivery Systems™ can improve increased vaccine effectiveness, allow for a preferred patient and caregiver experience, and offer a proven path to commercialization. They are also safe, fast, and easy-to-use. The Stratis ® System has U.S. FDA 510(k) marketing clearance, CE Mark, and WHO PQS certification to deliver medications and vaccines either intramuscularly or subcutaneously. The Tropis ® System has CE Mark and WHO PQS certification for intradermal injections. They are both commercially available for global immunization programs. For more information or if you are interested in partnering with PharmaJet to improve the impact of your novel development program, visit https://pharmajet.com or contact PharmaJet here . Follow us on LinkedIn . About Scancell Scancell is a clinical stage biopharmaceutical company that is leveraging its proprietary research, built up over many years of studying the human adaptive immune system, to generate novel medicines to treat significant unmet needs in cancer. The Company is building a pipeline of innovative products by utilising its four technology platforms: Moditope® and ImmunoBody® for vaccines and GlyMab® and AvidiMab® for antibodies. Adaptive immune responses include antibodies and T cells (CD4 and CD8), both of which can recognise damaged or infected cells. In order to destroy such cancerous or infected cells, Scancell uses either vaccines to induce immune responses or monoclonal antibodies (mAbs) to redirect immune cells or drugs. The Company’s unique approach is that its innovative products target modifications of proteins and lipids. For the vaccines (Moditope® and ImmunoBody® ) this includes citrullination and homocitrullination of proteins, whereas its mAb portfolio targets glycans or sugars that are added onto proteins and / or lipids (GlyMab® ) or enhances the potency of antibodies and their ability to directly kill tumour cells (AvidiMab® ). For further information about Scancell, please visit: https://www.scancell.co.uk/

Delivery of a novel self-amplifying mRNA (samRNA)-based vaccine with Tropis ID System directly into the dermis significantly boosts immune responses. This study shows that intradermal (ID) delivery of a samRNA vaccine with liquid nano-emulsion is safe and well-tolerated. GEMCOVAC®-OM samRNA vaccine is a low dose, room temperature stable mRNA vaccine that was licensed under emergency use authorization in 2023. GOLDEN, Colo.--(BUSINESS WIRE)-- PharmaJet®, a company that strives to improve the performance and outcomes of medicines with its innovative delivery systems, today announced the Nature publication1 of Gennova Biopharmaceutical’s Phase 2/3 clinical trial conducted to evaluate the safety and immunogenicity of its novel samRNA-based Covid-19 vaccine booster. The results demonstrated that GEMCOVAC-OM, administered exclusively with Tropis, is well-tolerated with no related serious adverse events and significantly boosts immune responses against the Omicron variant. Furthermore, the publication cited that the self-amplifying, thermostable mRNA platform delivered intradermally with Tropis provides a framework for next-generation vaccines that can improve accessibility and global equity. This press release features multimedia. View the full release here: The PharmaJet pioneering technology unlocks the rich potential of the human dermis, paving the way for enhanced immune responses. (Graphic: Business Wire) ID delivery is known to have the potential to improve the performance of vaccines, but this study is the first time a samRNA vaccine has been developed with a lipid nano-emulsion, and the data show that ID administration of this vaccine is safe and well-tolerated. Tropis unlocks the rich potential of the human dermis, paving the way for enhanced immune responses. Vaccine delivery directly into the dermis enables access to the immune system, with benefits on durability and breadth of immune response, and mucosal immunity. Tropis also enables access to immune cell populations more directly thus creating the potential for dose sparing. PharmaJet has partnered with Gennova to improve the performance and outcomes of their samRNA platform with PharmaJet’s breakthrough ID delivery technology. The outcome of this collaboration is a needle-free self-amplifying vaccine with advantages over the other mRNA vaccines approved for COVID-19: GEMCOVAC-OM is a lyophilized vaccine, stable at 2-8°C, which means it can be distributed through the existing refrigeration supply chain. The booster vaccine is exclusively administered intradermally with Tropis. Tropis leverages the rich network of dendritic cells, macrophages, and T cells in the dermal layer providing a more potent and broader immunogenic response than vaccinating into the muscle. Tropis is prequalified by the WHO and approved by numerous regulatory bodies globally. As a needle-free delivery System, Tropis eliminates the need for sharps disposal and needle-stick injuries, as well as increases coverage due to its high acceptability among caregivers and healthcare workers. “We congratulate our partner Gennova for their compelling data published in this prestigious journal,” said Chris Cappello, President, and Chief Executive Officer, PharmaJet. “This new data adds to the evidence base indicating Tropis needle-free ID administration is an enabler for vaccine platforms.” Tropis ID (for intradermal administration) and Stratis® SC/IM (for intramuscular and subcutaneous administration) are the only commercially scaled needle-free technologies that enhance the performance of several vaccines and therapeutics. PharmaJet has over 80 global development partners and Tropis has been used to perform over 10 million vaccinations in several countries. For more information about PharmaJet visit . Refer to Instructions for Use to ensure safe injections and to review risks. 1 An Omicron-specific, self-amplifying mRNA booster vaccine for COVID-19: a phase 2/3 randomized trial | Nature Medicine About PharmaJet The PharmaJet mission is to improve the performance and outcomes of medicines with our innovative delivery systems that better activate the immune system. We are committed to helping our partners realize their research and commercialization goals while making an impact on public health. PharmaJet Precision Delivery Systems™ can improve increased vaccine effectiveness, allow for a preferred patient and caregiver experience, and offer a proven path to commercialization. They are also safe, fast, and easy-to-use. The Stratis® System has U.S. FDA 510(k) marketing clearance, CE Mark, and WHO PQS certification to deliver medications and vaccines either intramuscularly or subcutaneously. The Tropis® System has CE Mark and WHO PQS certification for intradermal injections. They are both commercially available for global immunization programs. For more information or if you are interested in partnering with PharmaJet to improve the impact of your novel development program, visit or contact PharmaJet here. Follow us on LinkedIn. View source version on businesswire.com: Contacts Nancy Lillie Nancy.Lillie@pharmajet.com 1-888-900-4321 Option 3 Source: PharmaJet Smart Multimedia Gallery Photo The PharmaJet pioneering technology unlocks the rich potential of the human dermis, paving the way for enhanced immune responses. (Graphic: Business Wire) Logo View this news release and multimedia online at: